C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Julho 2023 - 8:00AM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced
that the independent directors serving on the Organization,
Leadership and Compensation Committee of the Company’s Board of
Directors approved the grant of non-qualified stock options to
purchase an aggregate of 351,000 shares of the Company’s common
stock to two new employees (the “Inducement Grants”), with grants
made on July 10 and July 17, 2023 (the “Grant Dates”).
The Inducement Grants were granted as inducements material to these
individuals entering into employment with C4T in accordance with
Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is
equal to the closing price of C4T’s common stock on their
respective Grant Dates. The Inducement Grants will vest over a
four-year period, with 25% of the shares vesting on the first-year
anniversary of the employee’s start date, and thereafter the
remainder of the shares vesting in twelve equal quarterly
installments, subject to each employee’s continued employment with
C4T through each vesting date.
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is leveraging its
TORPEDO® platform to efficiently design and optimize
small-molecule medicines that harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. C4T is advancing
multiple targeted oncology programs to the clinic and expanding its
research platform to deliver the next wave of medicines for
difficult-to-treat diseases. For more information, please
visit www.c4therapeutics.com.
Investor Contact: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media Contact: Loraine
Spreen Director, Corporate Communications & Patient
Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024